Activity of ceftolozane-tazobactam against Pseudomonas aeruginosa and Enterobacterales isolates recovered in Intensive Care Units in Spain: The SUPERIOR multicentre study.

•Activity of ceftolozane/tazobactam (C/T) against Enterobacterales and Pseudomonas aeruginosa collected from Spanish ICUs.•P. aeruginosa susceptibility to C/T was 95.7% in complicated UTIs and 85.3% in complicated IAIs.•The corresponding figures in Enterobacterales were 79.5% and 89.3%, respectively.•In vitro activity of C/T suggests that it can be considered as a therapeutic option in ICU patients.